Jasper Therapeutics Reports Positive Clinical Data for Briquilimab in Chronic Urticaria, Advancing to Phase 2b

summarizeSummary

Jasper Therapeutics announced positive updated clinical data from its BEACON Phase 1b/2a and open-label extension studies for briquilimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), demonstrating rapid and durable disease control with a favorable safety profile. The data supports advancing to a Phase 2b study in CSU in the second half of 2026.

check_boxKey Events

• Positive BEACON Study Data

  Briquilimab showed 67% complete response at 12 weeks and 83% complete response by week 3 in additional CSU patients, with a mean UAS7 reduction of 31 points.

• Favorable Open-Label Extension Results

  In the OLE study, 75% of CSU patients achieved complete response or well-controlled disease at 12 weeks, and 65% of CIndU patients achieved a clinical response at 16 weeks.

• Strong Safety Profile

  Briquilimab was well-tolerated across both studies, with low frequency and predominantly low-grade KIT-related adverse events over a median follow-up of over 200 days.

• Advancement to Phase 2b

  The company has sufficient data to select doses for a planned Phase 2b study in CSU, expected to commence in the second half of 2026.

auto_awesomeAnalysis

This 8-K filing is highly significant for Jasper Therapeutics as it provides strong clinical validation for briquilimab, its lead therapeutic candidate for chronic urticaria. The positive efficacy and safety data from both the BEACON and open-label extension studies de-risk the development program and provide a clear path forward to a Phase 2b study. For a clinical-stage biotechnology company, successful progression through clinical trials is critical for investor confidence and future valuation. The favorable safety profile, coupled with rapid and durable responses, suggests a potentially differentiated product in a market with unmet needs. Investors should monitor the initiation and progress of the planned Phase 2b study.